|
Sign In to gain access to subscriptions and/or personal tools.
|
The Assessment of Local Tolerance, Acute Toxicity, and DNA Biodistribution Following Particle-Mediated Delivery of a DNA Vaccine to Minipigs
Andrew M. Pilling
Pathology Department, Safery Assessment, cGlaxoSmithKline, Ware Hertfordshire, United Kingdom, amp1069{at}gsk.com
Risa M. Harman
International Preclinical Safety Projects, Safety Assessment, GlaxoSmithKline, Ware, Hertfordshire, United Kingdom
Stewart A. Jones
Pathology Department, Safery Assessment, cGlaxoSmithKline, Ware Hertfordshire, United Kingdom
Nicola A.M. Mccormack
Pathology Department, Safery Assessment, cGlaxoSmithKline, Ware Hertfordshire, United Kingdom
Debbie Lavender
Pathology Department, Safery Assessment, cGlaxoSmithKline, Ware Hertfordshire, United Kingdom
Richard Haworth
Pathology Department, Safery Assessment, cGlaxoSmithKline, Ware Hertfordshire, United Kingdom
Particle-mediated DNA delivery was used to administer a DNA vaccine against Hepatitis B to minipigs. The study represented one arm of the safety evaluation program for this product and was designed to assess local tolerance, acute toxicity, and biodistribution of the DNA plasmid. The vaccine was given to 4 groups of minipigs that were sacrificed at 2, 28, 56, or 141 days after treatment. The procedure was well tolerated with mild local skin reactions at 2 days postdosing and no evidence of systemic toxicity. By 28 days the skin lesions had regressed apart from a low grade perivascular mononuclear cell infiltrate in the upper dermis, together with a small number of phagocytosed gold particles. This infiltrate persisted up to 141 days. The expressed HBsAg was detected by immunohistochemistry in keratinocytes (usually in association with an intranuclear gold particle) at 2 days but not at later time points. Polymerase chain reaction (PCR) was used to assay treatment sites and selected internal organs to evaluate biodistribution and persistence of the DNA plasmid. At 2 days the plasmid was detected in the treatment sites and also in the inguinal lymph nodes. At day 57 it was present in the treatment sites only and by day 141 appeared to have cleared. The results from this study demonstrate that particle-mediated gene delivery was well tolerated in the minipig. The biodistribution and persistence of the plasmid was within acceptabl e limits for this type of vaccine. As the minipig is regarded as a good model for humans these data support the concept that particle-mediated DNA delivery will be safe in human clinical applications.
Key Words: Gene-gun • safety studies • Hepatitis B Virus (HBV).
References
- Bauer SR (1999). Use and abuse of PCR assays for vector biodistribution studies: An FDA perspective. Available at http://www.fda.gov/cber/summaries/asgt060999sb.ppt.
- Boyle CM, Robinson HL (2000). Basic mechanisms of DNA-raised antibody responses to intramuscular and gene gun immunizations. DNA Cell Biol 19: 157—165.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Chen CH, Ji H., Suh KW, Choti MA, Pardoll DM, Wu TC (1999). Gene gun-mediated DNA vaccination induces antitumor immunity againsthuman papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 6: 1972—1981.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Chu CM, Liaw YF ( 1997). Natural history of chronic hepatitis B virus infection: An immunopathologica l study. J Gastroenterol Hepatol 12: S218—S222—.[Web of Science][Medline]
[Order article via Infotrieve]
- Ciccarelli RB, Pachuk JP, Samuel M., Winter LA, and Satishchandran C. (2001). Preclinical safety of DNA vaccines: A method to analyse the distribution of plasmid DNA in animal models. In: Methods in Molecular Medicine: DNA Vaccines: Methodsand Protocols, vol 29, Lowrie D, Whalen RG (eds). Humana Press, Totowa, NJ, pp 473—487.
- European Agency for the Evaluation of Medicinal Products (1998). Safety studies for gene therapy products: Annex to note for guidance on gene therapy product quality aspects in the production of vectors and genetically modified somatic cells. SWP/112/98. 63:36413: 1—7.
- Feltquate DM, Heaney S., Webster RG, Robinson HL (1997). Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunology 158: 2278—2284.[Abstract]
- Food and Drug Administration (1996). Points to consider on plasmid DNA vaccines for preventive infectious disease indications. Available at http://www.fda.gov/cber/cberftp.html.
- Food and Drug Administration ( 1998). Guidance for industry: Guidance for human somatic cell therapy and gene therapy. Fed Reg 36413.
- Gurunathan S., Klinman DM, Seder RA (2000). DNA vaccines: Immunology, application, and optimization. Ann Rev Immunol 18: 927—973.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Haworth R., Pilling AM (2000). The PCR assay in the preclinical safety evaluation of nucleic acid medicines. Human Exper Toxicol 19: 267— 276.
- Klinman DM, Takeno M., Ichino M., Gu M., Yamshchikov G., Mor G., Conover J. (1997). DNA vaccines: Safety and efficacy issues. SpringerSeminars in Immunopathology 19: 245—256.[CrossRef]
- Kurihara-Bergstrom T., Woodworth M., Feisullin S., Beall P. (1986). Characterization of the Yucatan miniature pig skin and small intestine for pharmaceutical applications. Lab Anim Sci 36: 396—399.[Web of Science][Medline]
[Order article via Infotrieve]
- Lavker RM, Dong G., Zheng PS, Murphy GF (1991). Hairless micropig skin. A novel model for studies of cutaneous biology. Amer J Pathol 138: 687—697.[Abstract]
- MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y., Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB (1998). First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J Infect Dis 178: 92—100.[Web of Science][Medline]
[Order article via Infotrieve]
- Macklin MD, McCabe D., McGregor MW, Neumann V., Meyer T., Callan R., Hinshaw VS, Swain WF (1998). Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 72: 1491—1496.[Abstract/Free Full Text]
- McAnulty PA (1999). The value of the minipig in toxicity and other studies supporting the development of new pharmaceuticals. Eur Pharmaceu Contractor 82—86.
- Merchant B. (1998). Gold, the noble metal and the paradoxes of its toxicology. Biologicals 26: 49—59.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Meyer W., Schwarz R., Neurand K. (1978). The skin of domestic mammals as a model for the human skin, with special reference to the domestic pig. Curr Prob Dermatol 7: 39—52.[CrossRef]
- Morris GM, Hopewell JW (1990). Epidermal cell kinetics of the pig: A review. Cell Tissue Kin 23: 271—282.[Web of Science][Medline]
[Order article via Infotrieve]
- Nichols WW, Ledwith BJ, Manam SV, Troilo PJ (0 AD). Potential DNA vaccine integration into host cell genome. Ann NY Acad Sci 772: 30—39.
- Porgador A., Irvine KR, Iwasaki A., Barber BH, Restifo NP, Germain RN (1998). Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exper Med 188: 1075—1082.[Abstract/Free Full Text]
- Qin L., Ding Y., Pahud DR, Chang E., Imperiale MJ, Bromberg JS (1997). Promoter attenuation in gene therapy: Interferon-gamm a and tumor necrosis factor-alpha inhibit transgene expression. Human Gene Ther 8: 2019—2029.
- RazE., CarsonDA, ParkerSE, ParrTB, Abai AM, AichingerG., Gromkowski SH, Singh M., Lew D., Yankaucka s MA (1994). Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 91: 9519—9523.[Abstract/Free Full Text]
- Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S., Culp J., Burkholder JK, Swain WF, Dixon RM, Widera G., Vessey R., King A., Ogg G., Gallimore A., Haynes JR, Heydenburg FD (2000). Induction of antigenspecific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19: 764—778.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Schirmbeck R., Bohm W., Ando K., Chisari FV, Reimann J. (1995). Nucleic acid vaccination primes hepatitis B virus surface antigen- specific cytotoxic T lymphocytes in nonresponder mice. J Virol 69: 5929—5934.[Abstract]
- Steele KE, Stabler K., VanderZandenL (2001). Cutaneous DNA vaccination against Ebola virus by particle bombardment: Histopathology and alteration of CD3-positive dendritic epidermal cells. Vet Pathol 38: 203—215.[Abstract/Free Full Text]
- Tacket CO, Roy MJ, Widera G., Swain WF, Broome S., Edelman R. (1999). Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17: 2826—2829.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Vana G., Meingassner JG (2000). Morphologic and immunohistochemical features of experimentally induced allergic contact dermatitis in Gottingen minipigs. Vet Pathol 37: 565—580.[Abstract/Free Full Text]
- Yager JA, Scott DW (1993). The skin and appendages. In: Pathology of Domestic Animals, Jubb KVF, Kennedy PC, Palmer N (eds). London, UK: Academic Press, p 545.
Toxicologic Pathology, Vol. 30, No. 3,
298-305 (2002)
DOI: 10.1080/01926230252929864
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
